Fibrodysplasia ossificans progressiva (FOP) is a very rare inherited connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles.
Fibrodysplasia Ossificans Progressiva (FOP) Treatment: Introduction
- Fibrodysplasia ossificans progressiva (FOP) is a very rare inherited connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles.
- This disorder specifically causes the body’s skeletal muscles and soft connective tissues to undergo a metamorphosis, essentially a transformation into bone, progressively locking joints in place and making movement difficult or impossible
Request Brochure for Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81771
Key Drivers of Global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market
- The global fibrodysplasia ossificans progressiva FOP treatment market is anticipated to expand rapidly in the near few years. Introduction of novel therapies and increase in cases of FOP are likely to be major drivers of the FOP treatment market.
- Rise in demand for FOP treatment and increase in awareness regarding FOP are also expected to drive the market during the forecast period
- According to the Journal of Rare Disease Research and Treatment, in 2016, the prevalence of FOP varied substantially from approximately 0.65 per million in North America, 0.47 per million in Western Europe, and 0.27 per million in Latin America to 0.05 per million in Africa and nearly 0.04 per million in the Asia Pacific
Corticosteroids to be Highly Attractive Segment
- In terms of drug class, the global fibrodysplasia ossificans progressiva (FOP) treatment market can be classified into corticosteroids, NSAIDs, bisphosphonates, and others
- The corticosteroids segment is expected to account for a major share of the global fibrodysplasia ossificans progressiva (FOP) treatment market by 2031, owing to a high usage of corticosteroids for the treatment of FOP that may help reduce the intense inflammation and tissue edema seen in the early stages of the disease.
Buy Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market Report –https://www.transparencymarketresearch.com/checkout.php?rep_id=81771<ype=S
Medication to be Highly Attractive Segment
- In terms of treatment, the global fibrodysplasia ossificans progressiva (FOP) treatment market can be classified into medication, occupational therapy, and others
- The medication segment is projected to account for a major share of the global fibrodysplasia ossificans progressiva (FOP) treatment market by 2031, as medications help in the treatment of disease in the early stages and hence, are prescribed mostly by physicians.
Oral to be Highly Attractive Segment
- In terms of route of administration, the global fibrodysplasia ossificans progressiva (FOP) treatment market can be classified into oral, topical, and parenteral
- Oral medications are mostly preferred for the treatment of FOP and hence, the segment is anticipated to hold a major share of the global fibrodysplasia ossificans progressiva (FOP) treatment market by 2031
Hospital Pharmacies to be Highly Lucrative Segment
- Based on distribution channel, the global fibrodysplasia ossificans progressiva (FOP) treatment market can be categorized into retail pharmacies, hospital pharmacies, online pharmacies, and others
- The hospitals segment is anticipated to account for a major share of the market in the next few years due to a rise in the number of FOP treatment in hospitals
Request for Analysis of COVID19 Impact on Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market –https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81771
North America to Offer Significant Opportunities in Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market
- In terms of region, the global fibrodysplasia ossificans progressiva (FOP) treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- North America accounted for a significant share of the global market in 2020 owing to favorable healthcare infrastructure, high per capita income, and high rate of adoption of advanced surgeries in the region
Key Players Operating in Global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market
The global fibrodysplasia ossificans progressiva (FOP) treatment market is semi-consolidated, with the presence of international and local players. Key players operating in the global fibrodysplasia ossificans progressiva (FOP) treatment market are:
- Pfizer Inc.
- AstraZeneca
- DAIICHI SANKYO COMPANY, LIMITED
- Regeneron Pharmaceuticals, Inc
- Blueprint Medicines Corporation
- Clementia
- Oncodesign
- La Jolla Pharmaceutical Company
- Novartis AG
- Ipsen Pharma
- BIOCRYST PHARMACEUTICALS, INC.
- Nobelpharma Co., Ltd
About Us
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Mr. Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/